论文信息 - An update on COVID-19 in paediatric and young adults with nephrotic syndrome, receiving chronic immunosuppression during the Omicron pandemic - 字舞流文

An update on COVID-19 in paediatric and young adults with nephrotic syndrome, receiving chronic immunosuppression during the Omicron pandemic

G. Ghiggeri | F. Lugani | E. Verrina | M. Bruschi | A. Angeletti | S. Palmeri | Carolina Bigatti

[1] J. Pego-Reigosa,et al. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study , 2021, RMD Open.

[2] P. Ravani,et al. Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol , 2021, BMJ Open.

[3] M. Prunotto,et al. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial , 2021, Journal of the American Society of Nephrology : JASN.

[4] G. Ghiggeri,et al. COVID-19 in Children with Nephrotic Syndrome on Anti-CD20 Chronic Immunosuppression. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[5] K. Bhaskaran,et al. Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.